Vital signs during infusion and observe for at least 1-hour post-infusion. Patients developing dermatologic toxicities should be monitored for the development of complications. Periodic monitoring of serum magnesium, calcium, and potassium are recommended to continue over an interval consistent with the half-life (8 weeks); monitor closely (during and after treatment) for cetuximab plus radiation therapy. KRASÂ genotyping of tumor tissue in patients with colorectal cancer.